Physician Search
 |
 |
 |
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Multiple Cancer Types
This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating
the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in
second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with
HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in
second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with
HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Head/Neck,
Phase I
I
Gibson, Mike
NCT03978689
VICCPHI1981
